ClinicalTrials.gg
BiosimilarDrug

QL2107 clinical trials

Also written QL2107.

A product of Pembrolizumab; its studies count on that page too.

studies test it
3
open now
2
in phase 3
2
first study started
2023

How each study uses QL2107 has had a first review. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the QL2107 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
4 Sept 2014 · KEYTRUDA · BLA 125514 (FDA, Drugs@FDA; as pembrolizumab)
European Union
17 Jul 2015 · Keytruda · EMEA/H/C/003820 (EMA; as pembrolizumab)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

QL2107
3

Studies by the year they started

3 studies that test it; most in 2025 (2)

Studies that test QL2107, by start year
YearStudies
20231
20252

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 0

Qilu Pharmaceutical Co., Ltd. (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 2 in phase 3

Studies that test QL2107, phase 3 first.

Studies

Open first, then newest update. How each study uses QL2107 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Tested on its own · 2 — no other medicine in its arm
Tested with established drugs · 1 — they are given beside it
Given beside what is tested · 7 — usual care or a partner of the new treatment
Start the discussion